[{"id":"075a5201-e3f8-44b6-8b44-76394d647793","acronym":"ALPHAMEDIX02","url":"https://clinicaltrials.gov/study/NCT05153772","created_at":"2021-12-10T23:53:34.786Z","updated_at":"2025-02-25T13:49:19.721Z","phase":"Phase 2","brief_title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","source_id_and_acronym":"NCT05153772 - ALPHAMEDIX02","lead_sponsor":"Radiomedix, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlphaMedix (SAR447873)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-27"},{"id":"bc4b4fca-c25c-497b-a1cb-b18eb877c1f0","acronym":"ALPHAMEDIX01","url":"https://clinicaltrials.gov/study/NCT03466216","created_at":"2021-01-19T15:42:04.464Z","updated_at":"2025-02-25T13:48:29.399Z","phase":"Phase 1","brief_title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","source_id_and_acronym":"NCT03466216 - ALPHAMEDIX01","lead_sponsor":"Radiomedix, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlphaMedix (SAR447873)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2021-08-24"}]